Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer
- 1 July 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (7) , 1105-1111
- https://doi.org/10.1016/0277-5379(89)90396-9
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer PatientsClinical Pharmacokinetics, 1987
- ENDOCRINE EFFECTS OF LOW DOSE AMINOGLUTETHIMIDE AS AN AROMATASE INHIBITOR IN THE TREATMENT OF BREAST CANCERClinical Endocrinology, 1985
- EFFECTS OF AMINOGLUTETHIMIDE ON ADRENAL STEROID SECRETIONClinical Endocrinology, 1983
- Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancerBritish Journal of Cancer, 1983
- Aminoglutethimide dose and hormone suppression in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Stereoselective Inhibition of Aromatase by Enantiomers of Aminoglutethimide*Endocrinology, 1979
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978
- Source of Estrogen Production in Postmenopausal Women1Journal of Clinical Endocrinology & Metabolism, 1973
- Aminoglutethimide (Elipten-Ciba) as an Inhibitor of Adrenal Steroidogenesis: Mechanism of Action and Therapeutic TrialJournal of Clinical Endocrinology & Metabolism, 1967
- Inhibition of Adrenal Corticosteroid Synthesis by Aminoglutethimide: Studies of the Mechanism of Action1Journal of Clinical Endocrinology & Metabolism, 1967